Sargent Investment Group LLC Acquires 47 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Sargent Investment Group LLC boosted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 7.1% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 711 shares of the medical research company’s stock after buying an additional 47 shares during the period. Sargent Investment Group LLC’s holdings in Thermo Fisher Scientific were worth $395,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in TMO. Legacy Investment Solutions LLC bought a new stake in Thermo Fisher Scientific during the third quarter worth about $26,000. Peterson Financial Group Inc. bought a new stake in Thermo Fisher Scientific during the third quarter worth about $27,000. Missouri Trust & Investment Co bought a new stake in Thermo Fisher Scientific during the fourth quarter worth about $29,000. Endeavor Private Wealth Inc. bought a new stake in Thermo Fisher Scientific during the fourth quarter worth about $30,000. Finally, RPg Family Wealth Advisory LLC bought a new stake in Thermo Fisher Scientific during the third quarter worth about $50,000. Institutional investors own 89.23% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have issued reports on TMO. Wells Fargo & Company lifted their price target on Thermo Fisher Scientific from $660.00 to $680.00 and gave the stock an “overweight” rating in a research note on Friday, January 31st. Raymond James reissued an “outperform” rating and issued a $667.00 target price (up previously from $650.00) on shares of Thermo Fisher Scientific in a research note on Monday. Barclays lowered their target price on Thermo Fisher Scientific from $620.00 to $610.00 and set an “equal weight” rating for the company in a research note on Wednesday, October 23rd. Robert W. Baird lowered their target price on Thermo Fisher Scientific from $632.00 to $622.00 and set an “outperform” rating for the company in a research note on Thursday, October 24th. Finally, Royal Bank of Canada lowered their target price on Thermo Fisher Scientific from $767.00 to $718.00 and set an “outperform” rating for the company in a research note on Thursday, October 24th. Four analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the stock. According to MarketBeat.com, Thermo Fisher Scientific has an average rating of “Moderate Buy” and a consensus price target of $658.00.

Insider Transactions at Thermo Fisher Scientific

In related news, CFO Stephen Williamson sold 9,825 shares of the company’s stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total value of $5,753,421.75. Following the transaction, the chief financial officer now directly owns 27,296 shares of the company’s stock, valued at approximately $15,984,264.64. This represents a 26.47 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Gianluca Pettiti sold 300 shares of the company’s stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total value of $175,677.00. Following the completion of the transaction, the executive vice president now directly owns 16,363 shares in the company, valued at $9,582,009.17. This trade represents a 1.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 29,125 shares of company stock valued at $16,207,439 in the last ninety days. 0.34% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Stock Up 0.2 %

TMO stock opened at $581.72 on Thursday. Thermo Fisher Scientific Inc. has a fifty-two week low of $493.30 and a fifty-two week high of $627.88. The business’s 50 day moving average price is $544.31 and its two-hundred day moving average price is $571.88. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66. The company has a market capitalization of $222.51 billion, a price-to-earnings ratio of 35.19, a price-to-earnings-growth ratio of 4.06 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Thursday, January 30th. The medical research company reported $6.10 EPS for the quarter, topping analysts’ consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. As a group, analysts forecast that Thermo Fisher Scientific Inc. will post 23.29 earnings per share for the current fiscal year.

Thermo Fisher Scientific declared that its board has initiated a stock repurchase plan on Friday, November 15th that allows the company to repurchase $4.00 billion in outstanding shares. This repurchase authorization allows the medical research company to repurchase up to 2% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company’s management believes its stock is undervalued.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.